Auvelity europe approval or ema dextromethorphan bupropion?

Has EMA approved Auvelity (dextromethorphan + bupropion) in Europe?

Yes. Auvelity (dextromethorphan/bupropion) received a European Commission approval for the treatment of major depressive disorder in adults. The European approval is handled through the EMA process, but the final “approved for EU use” status comes from the European Commission. [1]

Is Auvelity the same medicine as “dextromethorphan bupropion”?

Yes. Auvelity is the brand name for the fixed-dose combination of dextromethorphan and bupropion. [1]

When did EMA/EU approval happen?

The approval date is tied to the EMA/European Commission decision for Auvelity in the EU, as reflected in EU regulatory listings. [1]

Where can I verify the exact EU regulatory status?

Check the EU medicine page for Auvelity (dextromethorphan/bupropion), which lists the marketing authorisation status, dates, and regulatory details. [1]

Patent/exclusivity checks for Europe (if you’re researching launch timing or competitors)

For related patent/exclusivity research around Auvelity’s active ingredients and EU timeline questions, DrugPatentWatch.com is a useful starting point. [2]

Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/auvelity
[2] https://www.drugpatentwatch.com